Skip to main content

Table 1 Clinical characteristics between the two groups

From: Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

Variables

Baseline

24 months

Least square means of baseline-adjusted changes

Sitagliptin (n = 55)

Conventional (n = 60)

p value

Sitagliptin (n = 55)

Conventional (n = 60)

p value

Sitagliptin (n = 55)

Conventional (n = 60)

p value

Age, year

69 ± 8

69 ± 9

0.973

      

Gender (male/female)

38/17

39/21

0.641

      

Body mass index, kg/m2

25.9 ± 3.3

24.8 ± 3.9

0.098

25.5 ± 3.4

24.6 ± 3.8

0.203

−0.10 ± 0.16

−0.13 ± 0.15

0.368

Systolic BP, mmHg

132 ± 17

129 ± 19

0.287

133 ± 16

130 ± 20

0.377

1.70 ± 2.20 (n = 54)

0.34 ± 2.09

0.656

Diastolic BP, mmHg

74 ± 11

71 ± 12

0.090

75 ± 13 (n = 54)

71 ± 11

0.076

1.76 ± 1.47 (n = 54)

−0.54 ± 1.40

0.263

Heart rate, beats/min

70 ± 12

67 ± 12

0.196

71 ± 16

67 ± 10

0.129

3.37 ± 1.49

−2.14 ± 1.43

0.009

Total cholesterol, mmol/L

4.4 ± 0.8

4.6 ± 0.9

0.43

4.4 ± 0.8 (n = 54)

4.4 ± 1.0

0.690

−0.08 ± 0.09 (n = 54)

−0.10 ± 0.08

0.899

HDL cholesterol, mmol/L

1.3 ± 0.3 (n = 55)

1.4 ± 0.4 (n = 58)

0.617

1.3 ± 0.3 (n = 54)

1.4 ± 0.4

0.412

−0.03 ± 0.03 (n = 54)

0.00 ± 0.03 (n = 58)

0.362

Triglycerides, mmol/L

3.1 [2.2–4.5] (n = 54)

3.1 [2.3–4.2]

0.536

2.9 [2.2–5.0] (n = 54)

2.9 [2.1–3.9]

0.151

0.06 ± 0.06 (n = 53)

−0.08 ± 0.05

0.078

Creatinine, μmol/L

71.6 [61.9–86.6]

68.1 [59.2–89.3]

0.496

75.1 [62.8–87.5] (n = 54)

69.0 [61.0–98.1]

0.740

2.65 ± 1.77 (n = 54)

4.42 ± 1.77

0.345

eGFR, mL/min/1.73 m2

66.6 ± 15.9

67.3 ± 18.4

0.834

65.1 ± 14.1 (n = 54)

67.1 ± 19.7

0.757

−1.96 ± 1.10 (n = 54)

–3.18 ± 1.04

0.419

Fasting plasma glucose, mmol/L

7.5 ± 1.8 (n = 53)

7.1 ± 1.4

0.135

7.0 ± 1.6 (n = 54)

6.7 ± 1.7 (n = 58)

0.248

−0.41 ± 0.20 (n = 52)

−0.49 ± 0.19 (n = 58)

0.780

HbA1c, %

7.0 ± 0.6

6.9 ± 0.5

0.737

6.5 ± 0.6 (n = 54)

6.6 ± 0.7

0.412

−0.47 ± 0.08 (n = 52)

−0.34 ± 0.07 (n = 57)

0.211

1,5AG, µg/mL

13.9 [8.3–20.3] (n = 52)

15.6 [10.7–22.8] (n = 58)

0.086

16.4 [8.7–22.6]

15.1 [9.6–25.0] (n = 59)

0.747

2.55 ± 0.82 (n = 52)

0.95 ± 0.79 (n = 57)

0.165

NT-proBNP, pg/mL

111.5 [42.1–240.8] (n = 52)

99.6 [52.1–234.9] (n = 58)

0.848

114.5 [51.8–261.9]

114.1 [60.2–323.8] (n = 59)

0.673

0.09 ± 0.08 (n = 52)

0.16 ± 0.08 (n = 57)

0.535

High-sensitive CRP, ng/mL

540 [279–1100] (n = 52)

576 [236–1618] (n = 58)

0.952

478 [232–1150] (n = 55)

478 [199–1590] (n = 59)

0.984

−0.06 ± 0.16 (n = 52)

−0.06 ± 0.15 (n = 57)

0.983

Current smoker, n (%)

8 (17.4) (n = 46)

13 (28.3) (n = 46)

0.321

      

Hypertension, n (%)

45 (81.8)

46 (76.7)

0.497

      

Dyslipidemia, n (%)

42 (76.4)

42 (70.0)

0.530

      

Cerebrovascular disease, n (%)

8 (14.6)

4 (6.7)

0.226

      

Cardiovascular disease, n (%)

38 (69.1)

41 (68.3)

0.930

      

Chronic heart failure, n (%)

3 (5.5)

7 (11.7)

0.326

      

Medications

 ACE inhibitor or ARB

37 (67.3)

42 (70.0)

0.753

39 (70.9)

41 (68.3)

0.764

   

 β-blocker

12 (21.8)

11 (18.3)

0.641

13 (23.6)

12 (20.0)

0.637

   

 Diuretic

17 (30.9)

12 (20.0)

0.178

16 (29.1)

15 (25.0)

0.621

   

 Statin

42 (76.4)

40 (66.7)

0.251

39 (70.9)

39 (65.0)

0.498

   

 α-Glucosidase inhibitor, n (%)

23 (41.8)

30 (50.0)

0.455

18 (32.7)

38 (63.3)

0.001

   

 Glinide, n (%)

4 (7.3)

4 (6.7)

0.899

2 (3.6)

5 (8.3)

0.293

   

 Biguanide, n (%)

9 (16.4)

10 (16.7)

0.965

12 (21.8)

16 (26.7)

0.545

   

 Sulfonylurea, n (%)

9 (16.4)

12 (20.0)

0.638

4 (7.3)

18 (30.0)

0.002

   

 Thiazolidinedione, n (%)

11 (20.0)

18 (30.0)

0.283

9 (16.4)

23 (38.3)

0.009

   
  1. Data for categorical variables are given as number (%); data for continuous variables given as mean ± standard deviation or median [interquartile range]. Skewed data was calculated after logarithmic translation. In the right column, values are shown as baseline-adjusted least square mean ± standard error
  2. BP blood pressure, HDL high-density lipoprotein, eGFR estimated glomerular filtration rate, 1,5AG 1,5-anhydroglucitol,1,4-anhydro-d-glucitol, NT-proBNP N-terminal pro-brain natriuretic peptide, CRP C-reactive protein. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840